Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Received chemotherapy, radiation therapy, immunosuppressants or cytokine treatment within 4 weeks prior to study entry.
• •Have active obstructive hydronephrosis.
• •Had prior autologous hematopoietic stem cell transplant or any allogenic stem cell transplant.
• •Have active infection requiring IV antibiotics.
• •Have brain or leptomeningeal metastasis.
• •Had previous allergic reaction to iodine, previously received radioimmunotherapy or are currently receiving approved or experimental anti-cancer drugs.
• •Patients who are pregnant or breast feeding, have known HIV infection, or are Human anti-murine antibody (HAMA) positive.
• •Other criteria will be evaluated at the screening visit.